Information

Related Research Units

Research Overview

The goals of Mark Puder's research include:

  • the prevention and treatment of parenteral and enteral nutrition induced liver injury
  • understanding the role of angiogenesis and organ regeneration
  • the prevention of post-operative surgical adhesions 

Dr. Puder's research team is currently conducting a clinical study on the prevention of parenteral nutrition liver injury based on their laboratory findings. They are also preparing a clinical study on the prevention of surgical adhesions.

Research Background

1986-1987 | Intern in Pediatrics, Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT

1987-1988 | Resident in Pediatrics, Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT

1988-1989 | Intern in Surgery, New England Deaconess Hospital, Harvard Medical School, Boston, MA

1989-1991 | Resident in Surgery, New England Deaconess Hospital, Boston, MA

1991-1992 Research Fellow, Department of Cellular and Molecular Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA

1992-1996 | Graduate Student, School of Arts and Sciences, Division of Medical Sciences, Harvard University, Cambridge, MA

1993-1996 | Thesis Laboratory: Department of Medicine, Massachusetts General Hospital, Boston, MA

1997-1998 | Resident in Surgery, Beth Israel-Deaconess Hospital, Boston, MA

1998-1999 | Chief Resident in Surgery, Beth Israel-Deaconess Hospital Boston, MA

1999-2000 | Associate Chief Resident in Pediatric Surgery, Children's Hospital Boston, Harvard Medical School, Boston, MA

2000-2001 | Chief Resident in Pediatric Surgery, Children's Hospital Boston, Harvard Medical School, Boston, MA

Education

Medical School

Vanderbilt University School of Medicine
1986 Nashville TN

Internship

New England Deaconess Hospital
Boston MA

Internship

Yale New Haven Hospital
New Haven CT

Residency

Beth Isreal Deaconess Hospital
Boston MA

Fellowship

Boston Children's Hospital
Boston MA

Publications

  1. Fish oil lipid emulsion compared with soybean oil lipid emulsion in pediatric patients with parenteral nutrition-associated cholestasis: A cost-effectiveness study. JPEN J Parenter Enteral Nutr. 2024 Dec 21. View Abstract
  2. Intestinal failure-associated liver disease model: a reduced phytosterol intravenous lipid emulsion prevents liver injury. Pediatr Res. 2024 Nov 27. View Abstract
  3. Smooth muscle Cxcl12 activation is associated with vascular remodeling in flow-induced pulmonary hypertension. bioRxiv. 2024 Sep 10. View Abstract
  4. Intravenous lipid emulsions designed to meet preterm infant requirements increase plasma and tissue levels of docosahexaenoic acid and arachidonic acid in mice. Clin Nutr. 2024 Oct; 43(10):2273-2285. View Abstract
  5. Achieving Enteral Autonomy in Children with Intestinal Failure Following Inpatient Admission: A Case Series. J Pediatr. 2024 Dec; 275:114226. View Abstract
  6. Administration of 4% tetrasodium EDTA lock solution and central venous catheter complications in high-risk pediatric patients with intestinal failure: A retrospective cohort study. JPEN J Parenter Enteral Nutr. 2024 Jul; 48(5):624-632. View Abstract
  7. Fat malabsorption in short bowel syndrome: A review of pathophysiology and management. Nutr Clin Pract. 2024 Apr; 39 Suppl 1:S17-S28. View Abstract
  8. Inflammation drives pathogenesis of early intestinal failure-associated liver disease. Sci Rep. 2024 02 20; 14(1):4240. View Abstract
  9. Pla2g5 contributes to viral-like-induced lung inflammation through macrophage proliferation and LA/Ffar1 lung cell recruitment. Immunology. 2024 May; 172(1):144-162. View Abstract
  10. Direct thrombin inhibitors fail to reverse the negative effects of heparin on lung growth and function after murine left pneumonectomy. Am J Physiol Lung Cell Mol Physiol. 2024 Mar 01; 326(3):L213-L225. View Abstract
  11. A medium-chain fatty acid analogue prevents hepatosteatosis and decreases inflammatory lipid metabolites in a murine model of parenteral nutrition-induced hepatosteatosis. PLoS One. 2023; 18(12):e0295244. View Abstract
  12. A pneumonectomy model to study flow-induced pulmonary hypertension and compensatory lung growth. Cell Rep Methods. 2023 10 23; 3(10):100613. View Abstract
  13. Absorption of an engineered medium-chain fatty acid analogue in two short bowel syndrome minipig models. JPEN J Parenter Enteral Nutr. 2023 11; 47(8):1028-1037. View Abstract
  14. Efficient megakaryopoiesis and platelet production require phospholipid remodeling and PUFA uptake through CD36. Nat Cardiovasc Res. 2023 Aug; 2(8):746-763. View Abstract
  15. Pericytes Contribute to Flow-induced Pulmonary Hypertension. Am J Respir Cell Mol Biol. 2023 06; 68(6):705-708. View Abstract
  16. A Medium-Chain Fatty Acid Analogue Prevents Intestinal Failure-Associated Liver Disease in Preterm Yorkshire Piglets. Gastroenterology. 2023 09; 165(3):733-745.e9. View Abstract
  17. IMPOWER: a national patient-generated registry for intestinal malrotation exploring diagnosis, treatment, and surgical outcomes. Orphanet J Rare Dis. 2023 05 11; 18(1):113. View Abstract
  18. Ethanol lock therapy increases mechanical catheter complications in a pediatric intestinal failure population: A retrospective cohort study. JPEN J Parenter Enteral Nutr. 2023 07; 47(5):662-669. View Abstract
  19. PR1P, a VEGF-stabilizing peptide, reduces injury and inflammation in acute lung injury and ulcerative colitis animal models. Front Immunol. 2023; 14:1168676. View Abstract
  20. A Digestive Cartridge Reduces Parenteral Nutrition Dependence and Increases Bowel Growth in a Piglet Short Bowel Model. Ann Surg. 2023 10 01; 278(4):e876-e884. View Abstract
  21. Fat digestion using RELiZORB in children with short bowel syndrome who are dependent on parenteral nutrition: Protocol for a 90-day, phase 3, open labeled study. PLoS One. 2023; 18(3):e0282248. View Abstract
  22. Efficient megakaryopoiesis and platelet production require phospholipid remodeling and PUFA uptake through CD36. bioRxiv. 2023 Feb 12. View Abstract
  23. Targeting the lung endothelial niche to promote angiogenesis and regeneration: A review of applications. Front Mol Biosci. 2022; 9:1093369. View Abstract
  24. Direct thrombin inhibitors as alternatives to heparin to preserve lung growth and function in a murine model of compensatory lung growth. Sci Rep. 2022 12 07; 12(1):21117. View Abstract
  25. Incidence and development of cholestasis in surgical neonates receiving an intravenous mixed-oil lipid emulsion. JPEN J Parenter Enteral Nutr. 2023 01; 47(1):30-40. View Abstract
  26. Current and emerging adjuvant therapies in biliary atresia. Front Pediatr. 2022; 10:1007813. View Abstract
  27. Effects of systemic anticoagulation in a murine model of compensatory lung growth. Pediatr Res. 2023 Jun; 93(7):1846-1855. View Abstract
  28. [Prevención y manejo de la colestasis asociada a la nutrición parenteral y la enfermedad hepática asociada a la insuficiencia intestinal en los lactantes críticamente enfermos]. World Rev Nutr Diet. 2022; 122:408-430. View Abstract
  29. Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease. Lipids. 2022 07; 57(4-5):241-255. View Abstract
  30. Lipopolysaccharide-induced murine lung injury results in long-term pulmonary changes and downregulation of angiogenic pathways. Sci Rep. 2022 06 17; 12(1):10245. View Abstract
  31. An in-line digestive cartridge increases enteral fat and vitamin absorption in a porcine model of short bowel syndrome. Clin Nutr. 2022 05; 41(5):1093-1101. View Abstract
  32. Outcomes and Perioperative Nutritional Management in a Porcine Model of Short Bowel Syndrome. J Surg Res. 2022 06; 274:59-67. View Abstract
  33. Prediction of the Development of Severe Sepsis Among Children With Intestinal Failure and Fever Presenting to the Emergency Department. Pediatr Emerg Care. 2021 Dec 01; 37(12):e1366-e1372. View Abstract
  34. Use of Intravenous Soybean and Fish Oil Emulsions in Pediatric Intestinal Failure-Associated Liver Disease: A Multicenter Integrated Analysis Report on Extrahepatic Adverse Events. J Pediatr. 2022 02; 241:173-180.e1. View Abstract
  35. Deficiency in pigment epithelium-derived factor accelerates pulmonary growth and development in a compensatory lung growth model. FASEB J. 2021 10; 35(10):e21850. View Abstract
  36. Visual Dysfunction after Repetitive Mild Traumatic Brain Injury in a Mouse Model and Ramifications on Behavioral Metrics. J Neurotrauma. 2021 10 15; 38(20):2881-2895. View Abstract
  37. Prevention and Management of Parenteral Nutrition-Associated Cholestasis and Intestinal Failure-Associated Liver Disease in the Critically Ill Infant. World Rev Nutr Diet. 2021; 122:379-399. View Abstract
  38. Investigation of the mechanisms of VEGF-mediated compensatory lung growth: the role of the VEGF heparin-binding domain. Sci Rep. 2021 06 04; 11(1):11827. View Abstract
  39. Dietary ?-3 Fatty Acid Supplementation Improves Murine Sickle Cell Bone Disease and Reprograms Adipogenesis. Antioxidants (Basel). 2021 May 18; 10(5). View Abstract
  40. Free Fatty Acid Receptors as Mediators and Therapeutic Targets in Liver Disease. Front Physiol. 2021; 12:656441. View Abstract
  41. One-year Experience With Composite Intravenous Lipid Emulsion in Children on Home Parenteral Nutrition. J Pediatr Gastroenterol Nutr. 2021 03 01; 72(3):451-455. View Abstract
  42. Current strategies for managing intestinal failure-associated liver disease. Expert Opin Drug Saf. 2021 Mar; 20(3):307-320. View Abstract
  43. Fish Oil Emulsion Reduces Liver Injury and Liver Transplantation in Children with Intestinal Failure-Associated Liver Disease: A Multicenter Integrated Study. J Pediatr. 2021 03; 230:46-54.e2. View Abstract
  44. PR1P Stabilizes VEGF and Upregulates Its Signaling to Reduce Elastase-induced Murine Emphysema. Am J Respir Cell Mol Biol. 2020 10; 63(4):452-463. View Abstract
  45. Dupilumab-induced serum sickness-like reaction: an unusual adverse effect in a patient with atopic eczema. J Eur Acad Dermatol Venereol. 2021 Jan; 35(1):e30-e32. View Abstract
  46. Optimizing Duration of Empiric Management of Suspected Central Line-Associated Bloodstream Infections in Pediatric Patients with Intestinal Failure. J Pediatr. 2020 12; 227:69-76.e3. View Abstract
  47. Roxadustat (FG-4592) accelerates pulmonary growth, development, and function in a compensatory lung growth model. Angiogenesis. 2020 11; 23(4):637-649. View Abstract
  48. Free fatty acid receptor 4 activation protects against choroidal neovascularization in mice. Angiogenesis. 2020 08; 23(3):385-394. View Abstract
  49. Intravenous Fish Oil Monotherapy as a Source of Calories and Fatty Acids Promotes Age-Appropriate Growth in Pediatric Patients with Intestinal Failure-Associated Liver Disease. J Pediatr. 2020 04; 219:98-105.e4. View Abstract
  50. Growth in Infants and Children With Intestinal Failure-associated Liver Disease Treated With Intravenous Fish Oil. J Pediatr Gastroenterol Nutr. 2020 02; 70(2):261-268. View Abstract
  51. Antibiotic Susceptibility and Therapy in Central Line Infections in Pediatric Home Parenteral Nutrition Patients. J Pediatr Gastroenterol Nutr. 2020 01; 70(1):59-63. View Abstract
  52. Growth in Infants and Children with Intestinal Failure Associated-Liver Disease Treated with Intravenous Fish Oil. J Pediatr Gastroenterol Nutr. 2019 Nov 06. View Abstract
  53. Use of Fish Oil Intravenous Lipid Emulsions as Monotherapy in the Pediatric Intestinal Failure Patient: Beyond the Package Insert. Nutr Clin Pract. 2020 Feb; 35(1):108-118. View Abstract
  54. Metabolic and Inflammatory Effects of an ?-3 Fatty Acid-Based Eucaloric Ketogenic Diet in Mice With Endotoxemia. JPEN J Parenter Enteral Nutr. 2019 11; 43(8):986-997. View Abstract
  55. Alpha-tocopherol in intravenous lipid emulsions imparts hepatic protection in a murine model of hepatosteatosis induced by the enteral administration of a parenteral nutrition solution. PLoS One. 2019; 14(7):e0217155. View Abstract
  56. Trends of INR and Fecal Excretion of Vitamin K During Cholestasis Reversal: Implications in the Treatment of Neonates With Intestinal Failure-Associated Liver Disease. JPEN J Parenter Enteral Nutr. 2020 07; 44(5):951-958. View Abstract
  57. The evolving use of intravenous lipid emulsions in the neonatal intensive care unit. Semin Perinatol. 2019 11; 43(7):151155. View Abstract
  58. Omega-3 fatty acids are protective in hepatic ischemia reperfusion injury in the absence of GPR120 signaling. J Pediatr Surg. 2019 Nov; 54(11):2392-2397. View Abstract
  59. Fish oil-based injectable lipid emulsions containing medium-chain triglycerides or added a-tocopherol offer anti-inflammatory benefits in a murine model of parenteral nutrition-induced liver injury. Am J Clin Nutr. 2019 04 01; 109(4):1038-1050. View Abstract
  60. Fish oil protects the liver from parenteral nutrition-induced injury via GPR120-mediated PPAR? signaling. Prostaglandins Leukot Essent Fatty Acids. 2019 04; 143:8-14. View Abstract
  61. A Diet With Docosahexaenoic and Arachidonic Acids as the Sole Source of Polyunsaturated Fatty Acids Is Sufficient to Support Visual, Cognitive, Motor, and Social Development in Mice. Front Neurosci. 2019; 13:72. View Abstract
  62. An Intravenous Fish Oil-Based Lipid Emulsion Successfully Treats Intractable Pruritus and Cholestasis in a Patient with Microvillous Inclusion Disease. Hepatology. 2019 03; 69(3):1353-1356. View Abstract
  63. A paradoxical method to enhance compensatory lung growth: Utilizing a VEGF inhibitor. PLoS One. 2018; 13(12):e0208579. View Abstract
  64. Vascular Endothelial Growth Factor Enhances Compensatory Lung Growth in Piglets. Surgery. 2018 12; 164(6):1279-1286. View Abstract
  65. Effects of dietary omega-3 fatty acids on bones of healthy mice. Clin Nutr. 2019 10; 38(5):2145-2154. View Abstract
  66. Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a Critical Mediator of Tissue Repair and Regeneration. Am J Pathol. 2018 11; 188(11):2446-2456. View Abstract
  67. Heparin impairs angiogenic signaling and compensatory lung growth after left pneumonectomy. Angiogenesis. 2018 11; 21(4):837-848. View Abstract
  68. Intranasal delivery of VEGF enhances compensatory lung growth in mice. PLoS One. 2018; 13(6):e0198700. View Abstract
  69. Essential Fatty Acid Status in Surgical Infants Receiving Parenteral Nutrition With a Composite Lipid Emulsion: A Case Series. JPEN J Parenter Enteral Nutr. 2019 02; 43(2):305-310. View Abstract
  70. Vascular endothelial growth factor accelerates compensatory lung growth by increasing the alveolar units. Pediatr Res. 2018 06; 83(6):1182-1189. View Abstract
  71. Commentary on "Fish Oil-Containing Lipid Emulsions in Adult Parenteral Nutrition: A Review of the Evidence". JPEN J Parenter Enteral Nutr. 2019 05; 43(4):454-455. View Abstract
  72. Central Line-Associated Bloodstream Infection among Children with Intestinal Failure Presenting to the Emergency Department with Fever. J Pediatr. 2018 05; 196:237-243.e1. View Abstract
  73. Pretreatment with intravenous fish oil reduces hepatic ischemia reperfusion injury in a murine model. Surgery. 2018 05; 163(5):1035-1039. View Abstract
  74. Parenteral Soybean Oil Induces Hepatosteatosis Despite Addition of Fish Oil in a Mouse Model of Intestinal Failure-Associated Liver Disease. JPEN J Parenter Enteral Nutr. 2018 02; 42(2):403-411. View Abstract
  75. Pediatric Intestinal Failure-Associated Liver Disease: Challenges in Identifying Clinically Relevant Biomarkers. JPEN J Parenter Enteral Nutr. 2018 02; 42(2):455-462. View Abstract
  76. Characterization of Fatty Acid Profiles in Infants With Intestinal Failure-Associated Liver Disease. JPEN J Parenter Enteral Nutr. 2018 01; 42(1):71-77. View Abstract
  77. Reducing Time to Antibiotics in Children With Intestinal Failure, Central Venous Line, and Fever. Pediatrics. 2017 Nov; 140(5). View Abstract
  78. Assessment of Micronutrient Status in Critically Ill Children: Challenges and Opportunities. Nutrients. 2017 Oct 28; 9(11). View Abstract
  79. An Evolving Story of Translational Research: A Decade after the Jacobson Promising Investigator Award. J Am Coll Surg. 2018 01; 226(1):100-103. View Abstract
  80. Lipids in the intensive care unit: Recommendations from the ESPEN Expert Group. Clin Nutr. 2018 02; 37(1):1-18. View Abstract
  81. Redefining essential fatty acids in the era of novel intravenous lipid emulsions. Clin Nutr. 2018 06; 37(3):784-789. View Abstract
  82. Response to Driscoll. JPEN J Parenter Enteral Nutr. 2017 07; 41(5):704-705. View Abstract
  83. Bioequivalence Demonstration for O-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance. Clin Ther. 2017 Mar; 39(3):652-658. View Abstract
  84. Use of a novel docosahexaenoic acid formulation vs control in a neonatal porcine model of short bowel syndrome leads to greater intestinal absorption and higher systemic levels of DHA. Nutr Res. 2017 Mar; 39:51-60. View Abstract
  85. Technique and perioperative management of left pneumonectomy in neonatal piglets. J Surg Res. 2017 05 15; 212:146-152. View Abstract
  86. Methods to Reduce Medication Errors in a Clinical Trial of an Investigational Parenteral Medication. Contemp Clin Trials Commun. 2016 Dec 15; 4:64-67. View Abstract
  87. Risk of post-procedural bleeding in children on intravenous fish oil. Am J Surg. 2017 Oct; 214(4):733-737. View Abstract
  88. Pediatric Intestinal Failure-Associated Liver Disease: Challenges in Identifying Clinically Relevant Biomarkers. JPEN J Parenter Enteral Nutr. 2016 Sep 28. View Abstract
  89. Intravenous Fat Emulsion Formulations for the Adult and Pediatric Patient: Understanding the Differences. Nutr Clin Pract. 2016 Oct; 31(5):596-609. View Abstract
  90. Predictors of failure of fish-oil therapy for intestinal failure-associated liver disease in children. Am J Clin Nutr. 2016 09; 104(3):663-70. View Abstract
  91. Higher Doses of Fish Oil-Based Lipid Emulsions Used to Treat Inadequate Weight Gain and Rising Triene:Tetraene Ratio in a Severely Malnourished Infant With Intestinal Failure-Associated Liver Disease. JPEN J Parenter Enteral Nutr. 2017 05; 41(4):667-671. View Abstract
  92. A Comparison of Fish Oil Sources for Parenteral Lipid Emulsions in a Murine Model. JPEN J Parenter Enteral Nutr. 2017 02; 41(2):181-187. View Abstract
  93. Eucaloric Ketogenic Diet Reduces Hypoglycemia and Inflammation in Mice with Endotoxemia. Lipids. 2016 06; 51(6):703-14. View Abstract
  94. Long-Term Fish Oil Lipid Emulsion Use in Children With Intestinal Failure-Associated Liver Disease [Formula: see text]. JPEN J Parenter Enteral Nutr. 2017 08; 41(6):930-937. View Abstract
  95. Lipid emulsions in the treatment and prevention of parenteral nutrition-associated liver disease in infants and children. Am J Clin Nutr. 2016 Feb; 103(2):629S-34S. View Abstract
  96. Intravenous Lipid Emulsions in Parenteral Nutrition. Adv Nutr. 2015 Sep; 6(5):600-10. View Abstract
  97. Clinically Relevant Mechanisms of Lipid Synthesis, Transport, and Storage. JPEN J Parenter Enteral Nutr. 2015 Sep; 39(1 Suppl):8S-17S. View Abstract
  98. Dietary ?-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease. Haematologica. 2015 Jul; 100(7):870-80. View Abstract
  99. Challenging the 48-Hour Rule-Out for Central Line-Associated Bloodstream Infections in the Pediatric Intestinal Failure Population: A Retrospective Pilot Study. JPEN J Parenter Enteral Nutr. 2016 05; 40(4):567-73. View Abstract
  100. The natural history of cirrhosis from parenteral nutrition-associated liver disease after resolution of cholestasis with parenteral fish oil therapy. Ann Surg. 2015 Jan; 261(1):172-9. View Abstract
  101. The addition of medium-chain triglycerides to a purified fish oil-based diet alters inflammatory profiles in mice. Metabolism. 2015 Feb; 64(2):274-82. View Abstract
  102. Elevated Alkaline Phosphatase in Infants With Parenteral Nutrition-Associated Liver Disease Reflects Bone Rather Than Liver Disease. JPEN J Parenter Enteral Nutr. 2015 Nov; 39(8):973-6. View Abstract
  103. Neonates with short bowel syndrome: an optimistic future for parenteral nutrition independence. JAMA Surg. 2014 Jul; 149(7):663-70. View Abstract
  104. The effect of docosahexaenoic acid on bone microstructure in young mice and bone fracture in neonates. J Surg Res. 2014 Sep; 191(1):148-55. View Abstract
  105. Docosahexaenoic acid, G protein-coupled receptors, and melanoma: is G protein-coupled receptor 40 a potential therapeutic target? J Surg Res. 2014 May 15; 188(2):451-8. View Abstract
  106. Treatment of parenteral nutrition-associated liver disease: the role of lipid emulsions. Adv Nutr. 2013 Nov; 4(6):711-7. View Abstract
  107. Neonatal intestinal physiology and failure. Semin Pediatr Surg. 2013 Nov; 22(4):190-4. View Abstract
  108. Evaluation of anastomotic strength and drug safety after short-term sunitinib administration in rabbits. J Surg Res. 2014 Mar; 187(1):101-6. View Abstract
  109. Intravenous fish oil lipid emulsion promotes a shift toward anti-inflammatory proresolving lipid mediators. Am J Physiol Gastrointest Liver Physiol. 2013 Dec; 305(11):G818-28. View Abstract
  110. Role of parenteral lipid emulsions in the preterm infant. Early Hum Dev. 2013 Oct; 89 Suppl 2:S45-9. View Abstract
  111. Scoliosis after chest wall resection. J Child Orthop. 2013 Oct; 7(4):301-7. View Abstract
  112. Epoxyeicosanoids promote organ and tissue regeneration. Proc Natl Acad Sci U S A. 2013 Aug 13; 110(33):13528-33. View Abstract
  113. A comparison of 2 intravenous lipid emulsions: interim analysis of a randomized controlled trial. JPEN J Parenter Enteral Nutr. 2014 Aug; 38(6):693-701. View Abstract
  114. The growing role of eicosanoids in tissue regeneration, repair, and wound healing. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug; 104-105:130-8. View Abstract
  115. A.S.P.E.N. clinical guidelines: nutrition support of neonatal patients at risk for metabolic bone disease. JPEN J Parenter Enteral Nutr. 2013 Sep; 37(5):570-98. View Abstract
  116. Mechanisms for the effects of fish oil lipid emulsions in the management of parenteral nutrition-associated liver disease. Prostaglandins Leukot Essent Fatty Acids. 2013 Sep; 89(4):153-8. View Abstract
  117. A metabolomic analysis of two intravenous lipid emulsions in a murine model. PLoS One. 2013; 8(4):e59653. View Abstract
  118. Fish oil-based lipid emulsion in the treatment of parenteral nutrition-associated liver disease. Curr Opin Pediatr. 2013 Apr; 25(2):193-200. View Abstract
  119. The role of the ?-3 fatty acid DHA in the human life cycle. JPEN J Parenter Enteral Nutr. 2013 Jan; 37(1):15-22. View Abstract
  120. The use of fish oil lipid emulsion in the treatment of intestinal failure associated liver disease (IFALD). Nutrients. 2012 Nov 27; 4(12):1828-50. View Abstract
  121. Response to Meyer and Gortner. JPEN J Parenter Enteral Nutr. 2013 Jan; 37(1):13-4. View Abstract
  122. The effect of varying ratios of docosahexaenoic acid and arachidonic acid in the prevention and reversal of biochemical essential fatty acid deficiency in a murine model. Metabolism. 2013 Apr; 62(4):499-508. View Abstract
  123. Prolonging the female reproductive lifespan and improving egg quality with dietary omega-3 fatty acids. Aging Cell. 2012 Dec; 11(6):1046-54. View Abstract
  124. Response to the letter to the editor regarding Nutrition support of neonatal patients at risk for necrotizing enterocolitis. JPEN J Parenter Enteral Nutr. 2013 Jan; 37(1):12. View Abstract
  125. Sunitinib reduces recurrent pelvic adhesions in a rabbit model. J Surg Res. 2012 Dec; 178(2):860-5. View Abstract
  126. Cholestasis and growth in neonates with gastroschisis. J Pediatr Surg. 2012 Aug; 47(8):1529-36. View Abstract
  127. Provision of a soy-based intravenous lipid emulsion at 1 g/kg/d does not prevent cholestasis in neonates. JPEN J Parenter Enteral Nutr. 2013 Jul; 37(4):498-505. View Abstract
  128. Hyperglycemia in the newborn--correctly reported. JPEN J Parenter Enteral Nutr. 2012 Jul; 36(4):379. View Abstract
  129. A.S.P.E.N. clinical guidelines: nutrition support of neonatal patients at risk for necrotizing enterocolitis. JPEN J Parenter Enteral Nutr. 2012 Sep; 36(5):506-23. View Abstract
  130. Dietary fish oil aggravates paracetamol-induced liver injury in mice. JPEN J Parenter Enteral Nutr. 2013 Mar; 37(2):268-73. View Abstract
  131. Effect of sunitinib on functional reproductive outcome in a rabbit model. Fertil Steril. 2012 Aug; 98(2):496-502. View Abstract
  132. A tutorial on fatty acid biology. JPEN J Parenter Enteral Nutr. 2012 Jul; 36(4):380-8. View Abstract
  133. Purified fish oil eliminating linoleic and alpha linolenic acid meets essential fatty acid requirements in rats. Metabolism. 2012 Oct; 61(10):1443-51. View Abstract
  134. Tissue-specific differences in inflammatory infiltrate and matrix metalloproteinase expression in adipose tissue and liver of mice with diet-induced obesity. Hepatol Res. 2012 Jun; 42(6):601-10. View Abstract
  135. Inhibition of neuroblastoma cell proliferation with omega-3 fatty acids and treatment of a murine model of human neuroblastoma using a diet enriched with omega-3 fatty acids in combination with sunitinib. Pediatr Res. 2012 Feb; 71(2):168-78. View Abstract
  136. A.S.P.E.N. Clinical Guidelines: hyperglycemia and hypoglycemia in the neonate receiving parenteral nutrition. JPEN J Parenter Enteral Nutr. 2012 Jan; 36(1):81-95. View Abstract
  137. Use of an omega-3 fatty acid-based emulsion in the treatment of parenteral nutrition-induced cholestasis in patients with microvillous inclusion disease. J Pediatr Surg. 2011 Dec; 46(12):2376-82. View Abstract
  138. Docosahexaenoic acid and arachidonic acid prevent essential fatty acid deficiency and hepatic steatosis. JPEN J Parenter Enteral Nutr. 2012 Jul; 36(4):431-41. View Abstract
  139. Tumor necrosis factor a-converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice. PLoS One. 2011; 6(9):e25587. View Abstract
  140. Arachidonic acid and docosahexaenoic acid supplemented to an essential fatty acid-deficient diet alters the response to endotoxin in rats. Metabolism. 2012 Mar; 61(3):395-406. View Abstract
  141. Parenteral fish-oil-based lipid emulsion improves fatty acid profiles and lipids in parenteral nutrition-dependent children. Am J Clin Nutr. 2011 Sep; 94(3):749-58. View Abstract
  142. Controlled release of vascular endothelial growth factor enhances intestinal adaptation in rats with extensive small intestinal resection. Surgery. 2011 Aug; 150(2):186-90. View Abstract
  143. Sunitinib inhibits postoperative adhesions in a rabbit model. Surgery. 2011 Jul; 150(1):32-8. View Abstract
  144. The prevention and treatment of intestinal failure-associated liver disease in neonates and children. Surg Clin North Am. 2011 Jun; 91(3):543-63. View Abstract
  145. Comparison of 5 intravenous lipid emulsions and their effects on hepatic steatosis in a murine model. J Pediatr Surg. 2011 Apr; 46(4):666-673. View Abstract
  146. Surgical intervention in the setting of parenteral nutrition-associated cholestasis may exacerbate liver injury. J Pediatr Surg. 2011 Jan; 46(1):122-7. View Abstract
  147. Parenteral fish oil as monotherapy improves lipid profiles in children with parenteral nutrition-associated liver disease. JPEN J Parenter Enteral Nutr. 2010 Sep-Oct; 34(5):477-84. View Abstract
  148. Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg. 2010 Sep; 97(9):1331-9. View Abstract
  149. Early development of essential fatty acid deficiency in rats: fat-free vs. hydrogenated coconut oil diet. Prostaglandins Leukot Essent Fatty Acids. 2010 Oct-Dec; 83(4-6):229-37. View Abstract
  150. Rapid infusion of fish oil-based emulsion in infants does not appear to be associated with fat overload syndrome. Nutr Clin Pract. 2010 Aug; 25(4):399-402. View Abstract
  151. Assessing portal fibrosis in parenteral nutrition-dependent patients treated with omega-3 fatty acid lipid emulsion. J Pediatr. 2010 Sep; 157(3):517; author reply 518. View Abstract
  152. Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS One. 2010 Jun 25; 5(6):e11256. View Abstract
  153. Prevention of parenteral nutrition-associated liver disease: role of omega-3 fish oil. Curr Opin Organ Transplant. 2010 Jun; 15(3):334-40. View Abstract
  154. Parenteral fish oil monotherapy in the management of patients with parenteral nutrition-associated liver disease. Arch Surg. 2010 Jun; 145(6):547-51. View Abstract
  155. Repetitive orogastric gavage affects the phenotype of diet-induced obese mice. Physiol Behav. 2010 Jun 16; 100(4):387-93. View Abstract
  156. Effects of metalloproteinase inhibition in a murine model of renal ischemia-reperfusion injury. Pediatr Res. 2010 Mar; 67(3):257-62. View Abstract
  157. Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition-dependent patients. J Pediatr Gastroenterol Nutr. 2010 Feb; 50(2):212-8. View Abstract
  158. Innovative parenteral and enteral nutrition therapy for intestinal failure. Semin Pediatr Surg. 2010 Feb; 19(1):27-34. View Abstract
  159. Effects of glucose or fat calories in total parenteral nutrition on fat metabolism and systemic inflammation in rats. Metabolism. 2011 Feb; 60(2):195-205. View Abstract
  160. Dietary fat intake promotes the development of hepatic steatosis independently from excess caloric consumption in a murine model. Metabolism. 2010 Aug; 59(8):1092-105. View Abstract
  161. Parenteral nutrition in the critically ill patient. N Engl J Med. 2010 Jan 07; 362(1):81-2; author reply 83-4. View Abstract
  162. Impact of fish oil-based lipid emulsion on serum triglyceride, bilirubin, and albumin levels in children with parenteral nutrition-associated liver disease. Pediatr Res. 2009 Dec; 66(6):698-703. View Abstract
  163. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg. 2009 Sep; 250(3):395-402. View Abstract
  164. Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience. JPEN J Parenter Enteral Nutr. 2009 Sep-Oct; 33(5):541-7. View Abstract
  165. The essentiality of arachidonic acid and docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep; 81(2-3):165-70. View Abstract
  166. Infant parenteral nutrition-associated cholestasis: a severe iatrogenic disease. JPEN J Parenter Enteral Nutr. 2010 Jan-Feb; 34(1):94-5. View Abstract
  167. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell. 2009 Mar 20; 136(6):1136-47. View Abstract
  168. Reduction of hepatocellular injury after common bile duct ligation using omega-3 fatty acids. J Pediatr Surg. 2008 Nov; 43(11):2010-5. View Abstract
  169. Parenteral fish oil as monotherapy for patients with parenteral nutrition-associated liver disease. Pediatr Surg Int. 2009 Jan; 25(1):123-4. View Abstract
  170. Pediatric rib lesions: a 13-year experience. J Pediatr Surg. 2008 Oct; 43(10):1781-5. View Abstract
  171. Prenatal diagnosis and subsequent treatment of an intermediate-risk paraspinal neuroblastoma: case report and review of the literature. Fetal Diagn Ther. 2008; 24(2):119-25. View Abstract
  172. Acid sphingomyelinase involvement in tumor necrosis factor alpha-regulated vascular and steroid disruption during luteolysis in vivo. Proc Natl Acad Sci U S A. 2008 Jun 03; 105(22):7670-5. View Abstract
  173. APC mutant zebrafish uncover a changing temporal requirement for wnt signaling in liver development. Dev Biol. 2008 Aug 01; 320(1):161-74. View Abstract
  174. Fish oil prevents essential fatty acid deficiency and enhances growth: clinical and biochemical implications. Metabolism. 2008 May; 57(5):698-707. View Abstract
  175. Newborn and toddler intestinal obstruction owing to congenital mesenteric defects. J Pediatr Surg. 2008 Apr; 43(4):755-8. View Abstract
  176. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics. 2008 Mar; 121(3):e678-86. View Abstract
  177. Re: Influence of different intravenous lipid emulsions on hepatobiliary dysfunction in a rabbit model. J Pediatr Gastroenterol Nutr. 2008 Feb; 46(2):224-5; author reply 225. View Abstract
  178. A critical role for matrix metalloproteinases in liver regeneration. J Surg Res. 2008 Apr; 145(2):192-8. View Abstract
  179. The role of an intravenous fat emulsion composed of fish oil in a parenteral nutrition-dependent patient with hypertriglyceridemia. Nutr Clin Pract. 2007 Dec; 22(6):664-72. View Abstract
  180. Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib. J Surg Res. 2008 Sep; 149(1):115-9. View Abstract
  181. Ablation of leptin signaling disrupts the establishment, development, and maintenance of endometriosis-like lesions in a murine model. Endocrinology. 2008 Feb; 149(2):506-14. View Abstract
  182. Endothelial progenitor cells contribute to accelerated liver regeneration. J Pediatr Surg. 2007 Jul; 42(7):1190-8. View Abstract
  183. Omega-3 fatty acids and liver disease. Hepatology. 2007 Apr; 45(4):841-5. View Abstract
  184. Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomy. Am J Physiol Lung Cell Mol Physiol. 2007 Mar; 292(3):L742-7. View Abstract
  185. Pediatric anorectal impalement with bladder rupture: case report and review of the literature. J Pediatr Surg. 2006 Sep; 41(9):E1-3. View Abstract
  186. Current clinical applications of omega-6 and omega-3 fatty acids. Nutr Clin Pract. 2006 Aug; 21(4):323-41. View Abstract
  187. Current Clinical Applications of O-6 and O-3 Fatty Acids. Nutr Clin Pract. 2006 Aug; 21(4):323-341. View Abstract
  188. Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. Am J Physiol Gastrointest Liver Physiol. 2006 Dec; 291(6):G1011-9. View Abstract
  189. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006 Jul; 118(1):e197-201. View Abstract
  190. Recent developments in aluminium contamination of products used in parenteral nutrition. Curr Opin Clin Nutr Metab Care. 2006 May; 9(3):239-46. View Abstract
  191. Microdeformational wound therapy: effects on angiogenesis and matrix metalloproteinases in chronic wounds of 3 debilitated patients. Ann Plast Surg. 2006 Apr; 56(4):418-22. View Abstract
  192. Acute necrotizing cholecystitis: a rare complication of ceftriaxone-associated pseudolithiasis. Pediatr Surg Int. 2006 Jun; 22(6):562-4. View Abstract
  193. Determining the need for simulated training of invasive procedures. Adv Health Sci Educ Theory Pract. 2006 Feb; 11(1):41-9. View Abstract
  194. Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells. FASEB J. 2006 Jan; 20(1):95-102. View Abstract
  195. Hyper and hypoglycemia of the neonate. American Society for Parenteral and Enteral Nutrition Clinical Guidelines. 2006. View Abstract
  196. Necrotizing enterocolitis. American Society for Parenteral and Enteral Nutrition Clinical Guidelines. 2006. View Abstract
  197. Metabolic bone disease. American Society for Parenteral and Enteral Nutrition Clinical Guidelines. 2006. View Abstract
  198. Use of Omega 3 Fatty Acids to Improve Liver Transplant Survival. 2006. View Abstract
  199. Tools for living better on home IV & tube feedings: HPN-Associated Liver Disease in Infants. 2006. View Abstract
  200. Hepatobiliary. American Society for Parenteral and Enteral Nutrition Clinical Guidelines. 2006. View Abstract
  201. Hypertriglyceridemia. American Society for Parenteral and Enteral Nutrition Clinical Guidelines. 2006. View Abstract
  202. Hands-Free Medical Device Management Waste Disposal System (Operating Room Table Sharps Container). 2006. View Abstract
  203. Distinct populations of circulating endothelial cells regulate liver regeneration and are an index of endothelial damage. J Pediatr Surg. 2006. View Abstract
  204. Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition. Clin Nutr. 2005 Oct; 24(5):839-47. View Abstract
  205. The route of lipid administration affects parenteral nutrition-induced hepatic steatosis in a mouse model. J Pediatr Surg. 2005 Sep; 40(9):1446-53. View Abstract
  206. Safety of an Intravenous Fish Oil Fat Emulsion When Used as Monotherapy in Infants Receiving Parenteral Nutrition: Preliminary Findings. European Society for Clinical Nutrition and Metabolism (ESPEN), 27th Congress of ESPEN, Brussels, Belgium. 2005. View Abstract
  207. Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib. Ann Surg. 2005 Jul; 242(1):140-6. View Abstract
  208. Pneumonectomy in the mouse: technique and perioperative management. J Invest Surg. 2005 Jul-Aug; 18(4):201-5. View Abstract
  209. Thymoma in a child: case report and review of the literature. Pediatr Surg Int. 2005 Jul; 21(7):548-51. View Abstract
  210. Patient-Friendly Stethoscope . 2005. View Abstract
  211. Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. Transplantation. 2005 Mar 15; 79(5):606-8. View Abstract
  212. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell. 2005 Mar; 7(3):251-61. View Abstract
  213. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005 Mar; 57(3):445-52. View Abstract
  214. Anal malformations in a two-generation family with split feet and TP63 mutation. 2005. View Abstract
  215. Treatment and Prevention of Fatty Liver Disease Associated with Total Parenteral Nutrition (TPN). 2004. View Abstract
  216. Urinary matrix metalloproteinases and their endogenous inhibitors predict hepatic regeneration after murine partial hepatectomy. Transplantation. 2004 Oct 27; 78(8):1139-44. View Abstract
  217. Method of Treating Fatty Liver Disease (MMPs). 2004. View Abstract
  218. Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency. Hepatology. 2004 Apr; 39(4):1176-7; author reply 1177-8. View Abstract
  219. Prevention of Surgical Adhesions via VEGF Receptor 2. 2004. View Abstract
  220. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med. 2004 Mar; 10(3):255-61. View Abstract
  221. Prevention of Surgical Adhesions Using Selective COX-2 Inhibitors. 2004. View Abstract
  222. Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg. 2003 Apr; 237(4):530-5. View Abstract
  223. Partial hepatectomy in the mouse: technique and perioperative management. J Invest Surg. 2003 Mar-Apr; 16(2):99-102. View Abstract
  224. GI bleeding. Hansen A, Puder M, editors. Manual of Neonatal Surgical Intensive Care. 2003. View Abstract
  225. Hansen A, Puder M. editors. Manual of Neonatal Surgical Intensive Care. 2003. View Abstract
  226. Chylothorax. Hansen A, Puder M, editors, Manual of Neonatal Surgical Intensive Care. 2003. View Abstract
  227. General surgical considerations. Hansen A, Puder M, editors. Manual of Neonatal Surgical Intensive Care. 2003. View Abstract
  228. Inguinal Hernia. Hansen A, Puder M, editors. Manual of Neonatal Surgical Intensive Care. 2003. View Abstract
  229. Bowel obstruction. Hansen A, Puder M, editors. Manual of Neonatal Surgical Intensive Care. 2003. View Abstract
  230. Vascular access. Hansen A, Puder M. editors. Manual of Neonatal Surgical Intensive Care. 2003. View Abstract
  231. Stoma management. Hansen A, Puder M, editors. Manual of Neonatal Surgical Intensive Care. 2003. View Abstract
  232. Gastrostomy tubes. Hansen A, Puder M, editors. Manual of Neonatal Surgical Intensive Care. 2003. View Abstract
  233. Hepatic exstrophy complicating Poland's anomaly. J Pediatr Surg. 2002 Aug; 37(8):1203-4. View Abstract
  234. A resident's guide to personal finance. Curr Surg. 2002 Jul-Aug; 59(4):423-5. View Abstract
  235. A holistic look at minimizing adverse environmental impact under Section 316(b) of the Clean Water Act. ScientificWorldJournal. 2002 Apr 18; 2 Suppl 1:41-57. View Abstract
  236. Cardiac relocation and chest wall reconstruction after separation of thoracopagus conjoined twins with a single heart. J Pediatr Surg. 2002 Mar; 37(3):515-7. View Abstract
  237. A resident's guide to personal finance. Curr Surg. 2002. View Abstract
  238. Intracellular binding of leukotriene C4 and glutathione conjugates [dissertation]. 1998. View Abstract
  239. Glutathione conjugates recognize the Rossmann fold of glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem. 1997 Apr 18; 272(16):10936-40. View Abstract
  240. Joining of DNA fragments by repeated cycles of denaturation, annealing and extension. Biotechniques. 1996 Jun; 20(6):954-5. View Abstract
  241. Arachidonic acid-derived mediators of inflammation. Tilney NC, Strom TB, et al, editors. Transplantation Biology: Cellular and Molecular Aspects. 1996. View Abstract
  242. Ubiquitin fusion proteins are overexpressed in colon cancer but not in gastric cancer. Biochim Biophys Acta. 1995 Dec 12; 1272(3):147-53. View Abstract
  243. Human ribosomal protein L37 has motifs predicting serine/threonine phosphorylation and a zinc-finger domain. Biochim Biophys Acta. 1994 Aug 02; 1218(3):425-8. View Abstract
  244. PCR product sequencing with [alpha-33P] and [alpha-32P]dATP. Biotechniques. 1994 Apr; 16(4):572-3. View Abstract
  245. Nucleotide and deduced amino acid sequence of human ribosomal protein L18. Biochim Biophys Acta. 1993 Oct 19; 1216(1):134-6. View Abstract
  246. Gastric and hepatocellular carcinomas do not overexpress the same ribosomal protein messenger RNAs as colonic carcinoma. Cancer Res. 1993 Sep 01; 53(17):4048-52. View Abstract
  247. The effect of delta 1tetrahydrocannabinol on luteinizing hormone release in castrated and hypothalamic deafferented male rats. Exp Brain Res. 1985; 59(2):213-6. View Abstract
  248. [Analgesic-antipyretic agents: which one?]. Harefuah. 1982 Mar 15; 102(6):258-61. View Abstract
  249. Corticotrophin and corticosterone secretion following delta 1-Tetrahydrocannabinol, in intact and in hypothalamic deafferentated male rats. Exp Brain Res. 1982; 46(1):85-8. View Abstract
  250. The ovulation blocking effect of cannabinoids: structure-activity relationships. Psychoneuroendocrinology. 1980 Jan; 5(1):53-62. View Abstract
  251. Changes in rodent thyroid hormones and cyclic-AMP following treatment with pineal indolic compounds. Arch Int Physiol Biochim. 1978 May; 86(2):353-62. View Abstract
  252. Acute effect of delta1-tetrahydrocannabinol on the hypothalamo-pituitary-ovarian axis in the rat. Neuroendocrinology. 1977; 23(1):31-42. View Abstract

Contact Mark Puder